No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy.

CONTEXT PATIENTS with acromegaly frequently display disturbances of glucose and lipid metabolism, which might contribute to their increased cardiovascular risk. Because insulin resistance and increased lipolysis have been linked to ectopic lipid deposition, altered lipid accumulation in the liver and the myocardium might contribute to metabolic and cardiac complications in these patients. OBJECTIVE The aim of this study was to investigate myocardial (MYCL) and hepatic lipid content (HCL), insulin sensitivity, and cardiac function in active acromegaly and after control of GH excess through transsphenoidal surgery. PATIENTS Ten patients with newly diagnosed acromegaly (ACRO_active) were compared with 12 healthy controls (CON), matched for age, body mass index, and gender. In seven patients GH excess was controlled, and they were compared with their active state. METHODS MYCL and HCL were assessed by (1)H-magnetic resonance spectroscopy, pericardial fat and cardiac function by (1)H-magnetic resonance imaging, and insulin sensitivity and secretion by an oral glucose tolerance test. RESULTS Although MYCL tended to be lower, HCL was significantly lower in ACRO_active compared with CON (HCL: 1.2% ± 1.2% vs 4.3% ± 3.5% of (1)H-magnetic resonance spectroscopy signal, P < .02). Parameters of systolic function and hypertrophy were significantly increased in ACRO_active compared with CON, as were insulin secretion and resistance. After the control of GH excess, HCL and MYCL remained unchanged, but pericardial fat was increased in the patients in whom GH excess was controlled (from 11.6 ± 5.5 to 14.7 ± 6.2 cm(2), P = .02). CONCLUSION Acromegaly represents a unique condition characterized by low myocardial and hepatic lipid content despite decreased insulin sensitivity, hyperinsulinemia, and hyperglycemia. Hence, ectopic lipid accumulation does not appear to contribute to cardiac morbidity, and increased lipid oxidation might counteract ectopic lipid accumulation in GH excess.

[1]  J. Francis,et al.  127 Early Manifestations of Diabetic Cardiomyopathy Assessed by Cardiac Magnetic Resonance Imaging and Spectroscopy , 2014, Heart.

[2]  C. Anderwald,et al.  Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[3]  D. Schoenfeld,et al.  Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity. , 2013, The Journal of clinical endocrinology and metabolism.

[4]  G. Reiter,et al.  Effects of Insulin Therapy on Myocardial Lipid Content and Cardiac Geometry in Patients with Type-2 Diabetes Mellitus , 2012, PloS one.

[5]  G. Reiter,et al.  Short-Term Hyperinsulinemia and Hyperglycemia Increase Myocardial Lipid Content in Normal Subjects , 2012, Diabetes.

[6]  A. Colao.  Improvement of cardiac parameters in patients with acromegaly treated with medical therapies , 2012, Pituitary.

[7]  A. Colao,et al.  Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. , 2011, European journal of endocrinology.

[8]  G. Reiter,et al.  Insulin resistance is not associated with myocardial steatosis in women , 2011, Diabetologia.

[9]  A. Kjær,et al.  Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides , 2010, Pituitary.

[10]  Ewald Moser,et al.  Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy. , 2010, European journal of radiology.

[11]  C. Fox,et al.  Relations of Insulin Resistance and Glycemic Abnormalities to Cardiovascular Magnetic Resonance Measures of Cardiac Structure and Function: The Framingham Heart Study , 2010, Circulation. Cardiovascular imaging.

[12]  L. Orci,et al.  Lipid homeostasis, lipotoxicity and the metabolic syndrome. , 2010, Biochimica et biophysica acta.

[13]  G. Aquaro,et al.  Effects of somatostatin analogues on acromegalic cardiomyopathy: Results from a prospective study using cardiac magnetic resonance , 2010, Journal of endocrinological investigation.

[14]  J. Loeffler,et al.  Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. , 2010, The Journal of clinical endocrinology and metabolism.

[15]  P. Iozzo,et al.  Contribution of glucose tolerance and gender to cardiac adiposity. , 2009, The Journal of clinical endocrinology and metabolism.

[16]  M. Bredella,et al.  Peak growth hormone-releasing hormone-arginine-stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity. , 2009, The Journal of clinical endocrinology and metabolism.

[17]  B. S. Mohammed,et al.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity , 2009, Proceedings of the National Academy of Sciences.

[18]  A Luger,et al.  Decreased peripheral insulin sensitivity in acromegalic patients. , 2009, Experimental and clinical endocrinology.

[19]  N. Møller,et al.  Free fatty acids inhibit growth hormone/signal transducer and activator of transcription-5 signaling in human muscle: a potential feedback mechanism. , 2009, The Journal of clinical endocrinology and metabolism.

[20]  N. Møller,et al.  Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. , 2009, Endocrine reviews.

[21]  M. Roden,et al.  Effects of High-Dose Simvastatin Therapy on Glucose Metabolism and Ectopic Lipid Deposition in Nonobese Type 2 Diabetic Patients , 2009, Diabetes Care.

[22]  M. Roden,et al.  Ectopic lipids and organ function , 2009, Current opinion in lipidology.

[23]  G. Pacini,et al.  Reduced Basal ATP Synthetic Flux of Skeletal Muscle in Patients with Previous Acromegaly , 2008, PloS one.

[24]  Jeroen J. Bax,et al.  Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. , 2008, Journal of the American College of Cardiology.

[25]  Hanno Pijl,et al.  Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. , 2008, Journal of the American College of Cardiology.

[26]  A. Colao.  The GH–IGF‐I axis and the cardiovascular system: clinical implications , 2008, Clinical endocrinology.

[27]  Fritz Schick,et al.  Identification and characterization of metabolically benign obesity in humans. , 2008, Archives of internal medicine.

[28]  S. Heymsfield,et al.  Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. , 2008, The Journal of clinical endocrinology and metabolism.

[29]  H. Lamb,et al.  Progressive caloric restriction induces dose-dependent changes in myocardial triglyceride content and diastolic function in healthy men. , 2008, The Journal of clinical endocrinology and metabolism.

[30]  Jeroen J. Bax,et al.  Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. , 2007, Radiology.

[31]  L. Ellegård,et al.  Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults , 2005, Clinical endocrinology.

[32]  C. Cobelli,et al.  Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. , 2004, Diabetes.

[33]  G. Vitale,et al.  The heart: an end-organ of GH action. , 2004, European journal of endocrinology.

[34]  E. Moser,et al.  1H NMR relaxation times of skeletal muscle metabolites at 3 T , 2004, Magnetic Resonance Materials in Physics, Biology and Medicine.

[35]  P. Marzullo,et al.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management. , 2004, Endocrine reviews.

[36]  J. Schaffer,et al.  Lipotoxicity: when tissues overeat , 2003, Current opinion in lipidology.

[37]  M. Roden,et al.  Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. , 2002, Diabetes.

[38]  K Thomaseth,et al.  Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. , 2001, American journal of physiology. Endocrinology and metabolism.

[39]  M. Salvatore,et al.  Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. , 2001, The Journal of clinical endocrinology and metabolism.

[40]  Andrea Mari,et al.  A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test , 2001 .

[41]  H. Saito,et al.  Impaired β‐cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients , 2000, Clinical endocrinology.

[42]  T W Redpath,et al.  Determination of normal regional left ventricular function from cine-MR images using a semi-automated edge detection method. , 1999, Magnetic resonance imaging.

[43]  A. West,et al.  Noninvasive assessment of hepatic triglyceride content in humans with 13C nuclear magnetic resonance spectroscopy , 1996, Hepatology.

[44]  J. Jørgensen,et al.  Body fluids, circadian blood pressure and plasma renin during growth hormone administration: a placebo-controlled study with two growth hormone doses in healthy adults. , 1995, Scandinavian journal of clinical and laboratory investigation.

[45]  A. O’Sullivan,et al.  Body composition and energy expenditure in acromegaly. , 1994, The Journal of clinical endocrinology and metabolism.

[46]  K. Alberti,et al.  Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. , 1992, The Journal of clinical endocrinology and metabolism.

[47]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[48]  K. Alberti,et al.  Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man , 1989, Diabetologia.

[49]  P. Sönksen,et al.  Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. , 1967, The Journal of clinical endocrinology and metabolism.

[50]  L. Katznelson.  Alterations in body composition in acromegaly , 2008, Pituitary.